FINWIRES · TerminalLIVE
FINWIRES

RBC Downgrades Kymera Therapeutics to Sector Perform From Outperform, Lifts Price Target to $115 From $106, Keeps Speculative Risk

By

Kymera Therapeutics (KYMR) has an average rating of buy and mean price target of $124.19, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Related Articles

Research

Roth Capital Upgrades Comstock Resources to Neutral From Sell, $13 Price Target

Comstock Resources (CRK) has an average rating of hold and mean price target of $20.12, according to analysts polled by FactSet.Price: $12.94, Change: $-0.75, Percent Change: -5.48%

$CRK
Research

BofA Downgrades Weyerhaeuser to Neutral From Buy, Price Target is $26

Weyerhaeuser (WY) has an average rating of overweight and mean price target of $31.18, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $23.53, Change: $+1.03, Percent Change: +4.58%

$WY
Research

Raymond James Upgrades Weyerhaeuser to Strong Buy From Outperform, Price Target is $30

Weyerhaeuser (WY) has an average rating of overweight and mean price target of $31.18, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $23.53, Change: $+1.03, Percent Change: +4.58%

$WY